Biocept, Inc. Announces New Director Appointment - September 28, 2010

Biocept, Inc. Announces New Director Appointment - September 28, 2010

 

SAN DIEGO, Oct. 7 /PRNewswire/ -- Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, announced today the appointment of Bruce E. Gerhardt as Director.

"We are pleased to welcome Bruce to our Board. His experience will be invaluable to us as we move into our next stage of development," said Stephen M. Coutts, President and CEO.

Mr. Gerhardt has been a practicing Certified Public Accountant since 1986.  He is also a tax and business advisor providing tax compliance for small businesses and upper income individuals.  He earned his Bachelor of Arts Degree from the University of Southern California in 1973 and is a member of the American Institute of Certified Public

About Biocept

Biocept, an emerging biotechnology leader in cell separation technology, is developing novel diagnostic assays for personalized medicine in detection and monitoring of recurrent cancer. The CEE(TM) Cell Enrichment and Extraction platform combines sophisticated attachment chemistry with mathematically modeled fluid dynamics to enable earlier, accurate and less invasive diagnoses. Isolation, purification and genetic analysis of rare cells, such as circulating tumor cells, are managed within our state-of-the-art CLIA-accredited laboratory. The clinical laboratory is accredited by the College of American Pathologists (CAP) and holds licenses in California and several other states.

Visit: http://www.biocept.com/

SOURCE Biocept, Inc.

 

CONTACT: Stephen Coutts, +1-858-320-8283, for Biocept, Inc. 
 

Web Site: http://www.biocept.com

 

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.